肿瘤NGS全景变异检测探针设计中国专家共识(2026版)
随着肿瘤精准医学发展,基于NGS的CGP检测成为临床主流,但探针设计缺乏技术标准。中国医学科学院肿瘤医院联合多家权威机构,组织临床、病理及第三方检验专家,参考国内外文献并结合中国实践,针对目标基因及区域选择、基因组合方式、探针性能评估与变更等关键环节达成6条纲领性技术共识,系统提出探针池设计全流程技术规范。
要点
- 共识提出6条纲领性技术共识,覆盖目标基因及区域选择、基因组合、探针性能评估与变更等环节。
- 系统提出探针池设计全流程技术规范,填补肿瘤NGS探针设计技术标准空白。
- 共识为国家药监局对肿瘤NGS实验室自建方法的合规性审查提供科学依据。
核心结论
- 共识通过探针设计标准化、多层级性能验证体系构建及探针动态变更管理,推动肿瘤基因检测从「临床可用」向「临床可信」转变。
研究设计与样本
- 中国医学科学院北京协和医学院肿瘤医院联合中国抗癌协会病理专委会、中国食品药品检定研究院等权威机构,组织临床专家、病理专家及第三方医学检验机构代表深入研讨。
- 共识参考国内外文献并结合中国临床实践,针对CGP检测多个关键环节达成6条纲领性技术共识。
主要发现
- 共识针对目标基因及目标区域选择、基因组合方式、探针性能评估、探针变更等多个关键环节形成6条纲领性技术共识。
- 共识系统提出探针池设计全流程技术规范,填补了肿瘤NGS探针设计技术标准空白。
关键数值与推荐
- 共识形成6条纲领性技术共识,涵盖目标基因及区域选择、基因组合方式、探针性能评估、探针变更等关键环节。
- 共识建立多层级性能验证体系并对探针变更实施动态管理。
临床怎么用
- 临床可依据共识规范肿瘤NGS探针设计,覆盖目标基因及区域选择、基因组合、探针性能评估与变更管理。
- 共识为国家药监局对肿瘤NGS实验室自建方法的合规性审查提供科学依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comprehensive genomic profiling (CGP) based on next-generation sequencing (NGS) has emerged as a mainstream approach for clinical diagnosis and treatment with the development of precision oncology. However, as the first stage of NGS testing, probe design has not yet been standardized by a reliable assessment framework. In response to this unmet need, the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, in collaboration with the Tumor Pathology Committee of China Anti-Cancer Association, the National Institutes for Food and Drug Control, and other authoritative institutions, convened clinical experts, pathologists, and representatives from third-party medical laboratories for in-depth discussions on standardization strategies. The expert panel formulated six core technical consensus statements, including the selection of target genes and regions, gene combination strategies, probe performance evaluation, and probe updates, based on a thorough analysis of both international studies and domestic clinical experience. For the design of the probe pool, this consensus methodically suggests a full-process technical specification. It fills a technical gap in tumor NGS probe design by standardizing probe design, establishing a multi-level performance validation system, and dynamically managing probe modifications. Furthermore, it supports the shift of genomic testing from "clinically available" to "clinically reliable" by offering a scientific basis for the National Medical Products Administration's (NMPA) regulatory review of laboratory-developed tests (LDTs) for oncology. 随着肿瘤精准医学发展,基于二代测序(NGS)的肿瘤全景变异(CGP)检测成为临床诊疗的主流检测手段。然而,作为NGS检测的起始环节,探针设计尚未建立技术标准或评估体系。中国医学科学院北京协和医学院肿瘤医院联合中国抗癌协会病理专委会、中国食品药品检定研究院等权威机构组织临床专家、病理专家及第三方医学检验机构深入研讨,参考国内外文献,结合中国临床实践,针对CGP检测产品的目标基因及目标区域选择、基因组合方式、探针性能评估、探针变更等多个关键环节达成6条纲领性的技术共识,系统提出探针池设计全流程技术规范。共识通过探针设计标准化、多层级性能验证体系的构建及探针动态变更管理,填补了肿瘤NGS探针设计技术标准空白,为国家药品监督管理局对肿瘤NGS实验室自建方法的合规性审查提供科学依据,推动肿瘤基因检测从“临床可用”向“临床可信”转变。.
引用
- [Chinese expert consensus on NGS-based probe design for tumor comprehensive genomic profiling testing (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42086519. doi:10.3760/cma.j.cn112152-20250722-00356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。